查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572473

溶小體酸性脂肪酶缺乏症 (LAL-D) 治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032 年

Lysosomal Acid Lipase Deficiency (LAL-D) Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 90 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球溶小體酸性脂肪酶缺乏症(LAL-D) 治療市場價值為2.974 億美元，預計2024 年至2032 年複合年成長率為7.2%。認知和診斷的提高推動的以及基因檢測和酶替代療法（ERT）方面的進步。 《遺傳代謝疾病雜誌》2022 年的一項研究報告稱，接受 ERT 的患者在第一年內症狀改善了 50%，強調了其療效並創造了市場機會。

整個溶小體酸性脂肪酶缺乏症（LAL-D）治療產業根據適應症、治療類型和地區進行分類。

LAL-D 治療市場依適應症分為沃爾曼病 (WD) 和膽固醇酯貯積症 (CESD)。 WD 在全球市場佔據主導地位，預計在預測期內複合年成長率為 7.3%。 WD 的嚴重性和早發性推動了對有效治療的需求，包括 ERT 和標靶治療。此外，人們對早期診斷的認知不斷提高，基因檢測的進步也進一步推動了對 WD 治療的需求。此外，正在進行的 WD 新療法研究預計將有助於未來幾年的市場成長。

按治療類型分類，市場包括調脂藥物、支持性治療、酵素替代療法 (ERT) 和其他治療方法。 2023 年，ERT 佔據最高市場佔有率，達到 57.5%。 ERT 在治療嚴重肝臟和代謝併發症方面的有效性使其成為首選治療方法。 Sebelipase alfa 是唯一被批准用於 LAL-D 的 ERT，可改善肝功能、減少代謝症狀並預防疾病進展，從而增強其主導地位。此外，在新興市場擴大 ERT 治療範圍以及提高患者對治療方案的認知預計將促進 ERT 領域的成長。更有效的 ERT 治療方法的開發預計也將提高患者的治療效果和治療依從性。

2023年，美國LAL-D治療市場價值為1.001億美元，預計到預測期結束時將達到1.788億美元。美國因其先進的醫療基礎設施和專注於罕見疾病研究而領先北美市場。政府措施和 FDA 批准 ERT 作為第一線治療藥物極大地促進了市場成長。領先製藥公司和研究機構的存在進一步加速了有效治療方法的開發和可用性。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 對個人化醫療的需求不斷增加
      • 基因檢測的進展
      • 提高早期診斷和治療意識
      • 罕見疾病研究投資不斷增加
    • 產業陷阱與挑戰
      • 治療費用高
      • 嚴格的監管要求
  • 成長潛力分析
  • 監管環境
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按指標分類，2021 - 2032 年

  • 主要趨勢
  • 沃爾曼病 (WD)
  • 膽固醇酯貯積症（CESD）

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 酵素替代療法（ERT）
  • 支持性護理
  • 脂質調節劑
  • 其他治療類型

第 7 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 世界其他地區

第 8 章：公司簡介

  • Alexion Pharmaceuticals
  • Amgen Inc.
  • AstraZeneca
  • BioCrick BioTech
  • Lupin
  • Merck and Co., Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Zydus Group
簡介目錄
Product Code: 10859

The Global Lysosomal Acid Lipase Deficiency (LAL-D) Treatment Market was valued at USD 297.4 million in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2032. This growth is driven by increased awareness and diagnosis of rare genetic disorders, as well as advancements in genetic testing and enzyme replacement therapy (ERT). A 2022 study in the Journal of Inherited Metabolic Disease reported a 50% improvement in symptoms for patients receiving ERT within the first year, highlighting its efficacy and creating market opportunities.

The overall lysosomal acid lipase deficiency (LAL-D) treatment industry is classified based on the indication, treatment type, and region.

The LAL-D treatment market is segmented by indication into Wolman disease (WD) and cholesteryl ester storage disease (CESD). WD dominated the global market and is expected to grow at a 7.3% CAGR over the forecast period. WD's severity and early onset drive demand for effective treatments, including ERTs and targeted therapies. Moreover, increasing awareness about early diagnosis and advancements in genetic testing are further fueling the demand for WD treatments. Additionally, ongoing research into novel therapies for WD is anticipated to contribute to market growth in the coming years.

By treatment type, the market includes lipid-modifying agents, supportive care, enzyme replacement therapy (ERT), and other treatments. In 2023, ERT held the highest market share at 57.5%. ERT's effectiveness in managing severe hepatic and metabolic complications makes it the preferred treatment. Sebelipase alfa, the only approved ERT for LAL-D, improves liver function, reduces metabolic symptoms, and prevents disease progression, reinforcing its dominance. Furthermore, expanding access to ERT in emerging markets and increasing patient awareness about treatment options are expected to boost the ERT segment's growth. The development of more efficient ERT delivery methods is also projected to enhance patient outcomes and treatment adherence.

In 2023, the U.S. LAL-D treatment market was valued at USD 100.1 million and is anticipated to reach USD 178.8 million by the end of the forecast period. The U.S. leads the North American market due to its advanced healthcare infrastructure and focus on rare disease research. Government initiatives and FDA approvals for ERTs as first-line treatments have significantly contributed to market growth. The presence of leading pharmaceutical companies and research institutions further accelerates the development and availability of effective treatments.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing demand for personalized medicine
      • 3.2.1.2 Advancements in genetic testing
      • 3.2.1.3 Growing awareness for early diagnosis and treatment
      • 3.2.1.4 Rising investments in rare disease research
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of the treatment
      • 3.2.2.2 Stringent regulatory requirement
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Wolman disease (WD)
  • 5.3 Cholesteryl ester storage disease (CESD)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Enzyme replacement therapy (ERT)
  • 6.3 Supportive care
  • 6.4 Lipid modifying agents
  • 6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Rest of Europe
  • 7.4 Rest of the World

Chapter 8 Company Profiles

  • 8.1 Alexion Pharmaceuticals
  • 8.2 Amgen Inc.
  • 8.3 AstraZeneca
  • 8.4 BioCrick BioTech
  • 8.5 Lupin
  • 8.6 Merck and Co., Inc.
  • 8.7 Pfizer Inc.
  • 8.8 Regeneron Pharmaceuticals, Inc.
  • 8.9 Teva Pharmaceutical Industries Ltd.
  • 8.10 Thermo Fisher Scientific Inc.
  • 8.11 Zydus Group